CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.

doi:10.3389/fimmu.2023.1078958

Article

CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.

Frontiers in immunology - 1 Jan 2023

Bandara Geethani, Falduto Guido H, Luker Andrea, Bai Yun, Pfeiffer Annika, Lack Justin, Metcalfe Dean D, Olivera Ana

Abstract excerpt

The HMC-1.2 human mast cell (huMC) line is often employed in the study of attributes of neoplastic huMCs as found in patients with mastocytosis and their sensitivity to interventional drugs in vitro and in vivo. HMC-1.2 cells express constitutively active KIT, an essential growth factor receptor for huMC survival and function, due to the presence of two oncogenic mutations (D816V and V560G). However, systemic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.

Abstract excerpt

Topics

Related research